nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—prostate cancer	0.266	0.654	CbGaD
Haloperidol—CYP3A5—prostate cancer	0.0506	0.124	CbGaD
Haloperidol—CBR1—Doxorubicin—prostate cancer	0.0356	0.1	CbGbCtD
Haloperidol—CYP2C19—prostate cancer	0.0345	0.0845	CbGaD
Haloperidol—CYP1A1—prostate cancer	0.0343	0.0842	CbGaD
Haloperidol—CYP3A4—prostate cancer	0.0219	0.0537	CbGaD
Haloperidol—CYP1A1—Flutamide—prostate cancer	0.0201	0.0567	CbGbCtD
Haloperidol—CYP1A1—Estrone—prostate cancer	0.0146	0.041	CbGbCtD
Haloperidol—CYP3A5—Flutamide—prostate cancer	0.0121	0.034	CbGbCtD
Haloperidol—CYP2C19—Nilutamide—prostate cancer	0.0118	0.0331	CbGbCtD
Haloperidol—CYP2C19—Bicalutamide—prostate cancer	0.0118	0.0331	CbGbCtD
Haloperidol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0108	0.0305	CbGbCtD
Haloperidol—CYP2C9—Bicalutamide—prostate cancer	0.00978	0.0275	CbGbCtD
Haloperidol—CYP2C9—Nilutamide—prostate cancer	0.00978	0.0275	CbGbCtD
Haloperidol—CYP2C19—Flutamide—prostate cancer	0.00975	0.0274	CbGbCtD
Haloperidol—CYP1A2—Flutamide—prostate cancer	0.009	0.0253	CbGbCtD
Haloperidol—CYP2D6—Bicalutamide—prostate cancer	0.00895	0.0252	CbGbCtD
Haloperidol—CYP3A5—Cabazitaxel—prostate cancer	0.00894	0.0252	CbGbCtD
Haloperidol—ABCB1—Estramustine—prostate cancer	0.00883	0.0248	CbGbCtD
Haloperidol—CYP3A5—Estrone—prostate cancer	0.00874	0.0246	CbGbCtD
Haloperidol—CYP1A1—Estradiol—prostate cancer	0.00836	0.0235	CbGbCtD
Haloperidol—CYP2D6—Abiraterone—prostate cancer	0.00741	0.0209	CbGbCtD
Haloperidol—CYP3A7—Estradiol—prostate cancer	0.00669	0.0188	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00669	0.0188	CbGbCtD
Haloperidol—CYP1A2—Estrone—prostate cancer	0.00651	0.0183	CbGbCtD
Haloperidol—CYP2C9—Estrone—prostate cancer	0.00586	0.0165	CbGbCtD
Haloperidol—ABCB1—Cabazitaxel—prostate cancer	0.00582	0.0164	CbGbCtD
Haloperidol—CYP3A4—Bicalutamide—prostate cancer	0.00569	0.016	CbGbCtD
Haloperidol—ABCB1—Estrone—prostate cancer	0.00569	0.016	CbGbCtD
Haloperidol—CYP3A4—Estramustine—prostate cancer	0.00529	0.0149	CbGbCtD
Haloperidol—ABCB1—Ethinyl Estradiol—prostate cancer	0.00507	0.0143	CbGbCtD
Haloperidol—CYP3A5—Estradiol—prostate cancer	0.00502	0.0141	CbGbCtD
Haloperidol—CYP3A4—Flutamide—prostate cancer	0.00471	0.0133	CbGbCtD
Haloperidol—CYP3A4—Abiraterone—prostate cancer	0.00471	0.0133	CbGbCtD
Haloperidol—CYP2C9—Capecitabine—prostate cancer	0.00444	0.0125	CbGbCtD
Haloperidol—CYP1A2—Conjugated Estrogens—prostate cancer	0.00426	0.012	CbGbCtD
Haloperidol—CYP2C19—Estradiol—prostate cancer	0.00405	0.0114	CbGbCtD
Haloperidol—CYP3A7—Docetaxel—prostate cancer	0.004	0.0113	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.004	0.0113	CbGbCtD
Haloperidol—CYP1A2—Estradiol—prostate cancer	0.00374	0.0105	CbGbCtD
Haloperidol—ABCB1—Conjugated Estrogens—prostate cancer	0.00372	0.0105	CbGbCtD
Haloperidol—CYP3A4—Cabazitaxel—prostate cancer	0.00349	0.00982	CbGbCtD
Haloperidol—CYP2C19—Prednisone—prostate cancer	0.00348	0.0098	CbGbCtD
Haloperidol—CYP3A4—Estrone—prostate cancer	0.00341	0.00959	CbGbCtD
Haloperidol—ABCB1—Mitoxantrone—prostate cancer	0.00338	0.00952	CbGbCtD
Haloperidol—CYP2C9—Estradiol—prostate cancer	0.00337	0.00948	CbGbCtD
Haloperidol—CYP3A5—Etoposide—prostate cancer	0.00328	0.00923	CbGbCtD
Haloperidol—ABCB1—Estradiol—prostate cancer	0.00327	0.0092	CbGbCtD
Haloperidol—H1F0—semen—prostate cancer	0.0032	0.112	CbGeAlD
Haloperidol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00304	0.00855	CbGbCtD
Haloperidol—CYP3A5—Docetaxel—prostate cancer	0.003	0.00844	CbGbCtD
Haloperidol—ABCB1—Prednisone—prostate cancer	0.00281	0.00791	CbGbCtD
Haloperidol—CYP1A2—Etoposide—prostate cancer	0.00244	0.00687	CbGbCtD
Haloperidol—CYP3A4—Conjugated Estrogens—prostate cancer	0.00223	0.00628	CbGbCtD
Haloperidol—ABCB1—Etoposide—prostate cancer	0.00213	0.006	CbGbCtD
Haloperidol—CYP3A4—Mitoxantrone—prostate cancer	0.00203	0.00571	CbGbCtD
Haloperidol—CYP3A4—Estradiol—prostate cancer	0.00196	0.00551	CbGbCtD
Haloperidol—ABCB1—Docetaxel—prostate cancer	0.00195	0.00549	CbGbCtD
Haloperidol—CYP3A4—Prednisone—prostate cancer	0.00168	0.00474	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—prostate cancer	0.00146	0.0041	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—prostate cancer	0.00137	0.00386	CbGbCtD
Haloperidol—CYP2C19—urine—prostate cancer	0.00135	0.0473	CbGeAlD
Haloperidol—CYP3A4—Etoposide—prostate cancer	0.00128	0.0036	CbGbCtD
Haloperidol—CYP3A4—Docetaxel—prostate cancer	0.00117	0.00329	CbGbCtD
Haloperidol—CYP1A2—urine—prostate cancer	0.0011	0.0386	CbGeAlD
Haloperidol—CYP2C9—urine—prostate cancer	0.00104	0.0367	CbGeAlD
Haloperidol—CBR1—prostate gland—prostate cancer	0.00098	0.0344	CbGeAlD
Haloperidol—UGT1A9—renal system—prostate cancer	0.000887	0.0311	CbGeAlD
Haloperidol—CYP3A4—Doxorubicin—prostate cancer	0.000872	0.00245	CbGbCtD
Haloperidol—HTR2A—urine—prostate cancer	0.00086	0.0302	CbGeAlD
Haloperidol—CBR1—seminal vesicle—prostate cancer	0.000829	0.0291	CbGeAlD
Haloperidol—H1F0—prostate gland—prostate cancer	0.000803	0.0282	CbGeAlD
Haloperidol—CYP3A4—urine—prostate cancer	0.000797	0.028	CbGeAlD
Haloperidol—CYP2D6—urine—prostate cancer	0.000784	0.0275	CbGeAlD
Haloperidol—DRD4—testis—prostate cancer	0.000694	0.0243	CbGeAlD
Haloperidol—H1F0—seminal vesicle—prostate cancer	0.000679	0.0238	CbGeAlD
Haloperidol—CBR1—renal system—prostate cancer	0.000668	0.0234	CbGeAlD
Haloperidol—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00066	1	CbGdCrCtD
Haloperidol—CBR1—urethra—prostate cancer	0.000656	0.023	CbGeAlD
Haloperidol—SIGMAR1—prostate gland—prostate cancer	0.00058	0.0203	CbGeAlD
Haloperidol—H1F0—renal system—prostate cancer	0.000547	0.0192	CbGeAlD
Haloperidol—H1F0—urethra—prostate cancer	0.000537	0.0189	CbGeAlD
Haloperidol—CBR1—bone marrow—prostate cancer	0.000505	0.0177	CbGeAlD
Haloperidol—SIGMAR1—seminal vesicle—prostate cancer	0.00049	0.0172	CbGeAlD
Haloperidol—KCNH2—prostate gland—prostate cancer	0.000461	0.0162	CbGeAlD
Haloperidol—CBR1—testis—prostate cancer	0.000432	0.0151	CbGeAlD
Haloperidol—H1F0—bone marrow—prostate cancer	0.000414	0.0145	CbGeAlD
Haloperidol—KCNH2—seminal vesicle—prostate cancer	0.00039	0.0137	CbGeAlD
Haloperidol—SIGMAR1—urethra—prostate cancer	0.000388	0.0136	CbGeAlD
Haloperidol—CYP3A5—prostate gland—prostate cancer	0.000381	0.0134	CbGeAlD
Haloperidol—HRH1—prostate gland—prostate cancer	0.00037	0.013	CbGeAlD
Haloperidol—H1F0—testis—prostate cancer	0.000354	0.0124	CbGeAlD
Haloperidol—KCNH2—renal system—prostate cancer	0.000314	0.011	CbGeAlD
Haloperidol—CBR1—lymph node—prostate cancer	0.000313	0.011	CbGeAlD
Haloperidol—KCNH2—urethra—prostate cancer	0.000309	0.0108	CbGeAlD
Haloperidol—SIGMAR1—bone marrow—prostate cancer	0.000299	0.0105	CbGeAlD
Haloperidol—CYP1A1—epithelium—prostate cancer	0.000286	0.01	CbGeAlD
Haloperidol—HRH1—epithelium—prostate cancer	0.000272	0.00954	CbGeAlD
Haloperidol—CYP1A2—renal system—prostate cancer	0.000269	0.00945	CbGeAlD
Haloperidol—CYP1A1—renal system—prostate cancer	0.000266	0.00932	CbGeAlD
Haloperidol—CYP1A1—urethra—prostate cancer	0.000261	0.00916	CbGeAlD
Haloperidol—CYP3A5—renal system—prostate cancer	0.00026	0.00911	CbGeAlD
Haloperidol—H1F0—lymph node—prostate cancer	0.000256	0.009	CbGeAlD
Haloperidol—SIGMAR1—testis—prostate cancer	0.000255	0.00896	CbGeAlD
Haloperidol—HRH1—urethra—prostate cancer	0.000248	0.00869	CbGeAlD
Haloperidol—KCNH2—bone marrow—prostate cancer	0.000238	0.00835	CbGeAlD
Haloperidol—HTR2A—epithelium—prostate cancer	0.000227	0.00797	CbGeAlD
Haloperidol—HTR2A—renal system—prostate cancer	0.000211	0.00739	CbGeAlD
Haloperidol—DRD2—testis—prostate cancer	0.000206	0.00724	CbGeAlD
Haloperidol—KCNH2—testis—prostate cancer	0.000203	0.00713	CbGeAlD
Haloperidol—ABCB1—prostate gland—prostate cancer	0.000202	0.0071	CbGeAlD
Haloperidol—CYP3A4—renal system—prostate cancer	0.000195	0.00684	CbGeAlD
Haloperidol—CYP2D6—renal system—prostate cancer	0.000192	0.00673	CbGeAlD
Haloperidol—SIGMAR1—lymph node—prostate cancer	0.000185	0.0065	CbGeAlD
Haloperidol—HTR2B—lymph node—prostate cancer	0.000185	0.00648	CbGeAlD
Haloperidol—ABCB1—seminal vesicle—prostate cancer	0.000171	0.00601	CbGeAlD
Haloperidol—HRH1—testis—prostate cancer	0.000163	0.00572	CbGeAlD
Haloperidol—ABCB1—epithelium—prostate cancer	0.000149	0.00522	CbGeAlD
Haloperidol—KCNH2—lymph node—prostate cancer	0.000147	0.00517	CbGeAlD
Haloperidol—ABCB1—renal system—prostate cancer	0.000138	0.00484	CbGeAlD
Haloperidol—HTR2A—testis—prostate cancer	0.000136	0.00478	CbGeAlD
Haloperidol—ABCB1—urethra—prostate cancer	0.000136	0.00476	CbGeAlD
Haloperidol—CYP1A1—lymph node—prostate cancer	0.000124	0.00437	CbGeAlD
Haloperidol—CYP2D6—testis—prostate cancer	0.000124	0.00435	CbGeAlD
Haloperidol—HRH1—lymph node—prostate cancer	0.000118	0.00414	CbGeAlD
Haloperidol—ABCB1—bone marrow—prostate cancer	0.000104	0.00366	CbGeAlD
Haloperidol—ABCB1—testis—prostate cancer	8.92e-05	0.00313	CbGeAlD
Haloperidol—Moclobemide—CYP2C19—prostate cancer	8.06e-05	0.579	CrCbGaD
Haloperidol—ABCB1—lymph node—prostate cancer	6.46e-05	0.00227	CbGeAlD
Haloperidol—Dyspnoea—Etoposide—prostate cancer	3.98e-05	0.000348	CcSEcCtD
Haloperidol—Alopecia—Prednisone—prostate cancer	3.98e-05	0.000348	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—prostate cancer	3.96e-05	0.000347	CcSEcCtD
Haloperidol—Somnolence—Etoposide—prostate cancer	3.96e-05	0.000347	CcSEcCtD
Haloperidol—Vertigo—Capecitabine—prostate cancer	3.95e-05	0.000346	CcSEcCtD
Haloperidol—Hypersensitivity—Mitoxantrone—prostate cancer	3.95e-05	0.000346	CcSEcCtD
Haloperidol—Mental disorder—Prednisone—prostate cancer	3.94e-05	0.000345	CcSEcCtD
Haloperidol—Diarrhoea—Estradiol—prostate cancer	3.94e-05	0.000345	CcSEcCtD
Haloperidol—Leukopenia—Capecitabine—prostate cancer	3.94e-05	0.000345	CcSEcCtD
Haloperidol—Convulsion—Docetaxel—prostate cancer	3.93e-05	0.000345	CcSEcCtD
Haloperidol—Hypertension—Docetaxel—prostate cancer	3.92e-05	0.000343	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—prostate cancer	3.92e-05	0.000343	CcSEcCtD
Haloperidol—Malnutrition—Prednisone—prostate cancer	3.92e-05	0.000343	CcSEcCtD
Haloperidol—Sertindole—CYP3A4—prostate cancer	3.89e-05	0.279	CrCbGaD
Haloperidol—Decreased appetite—Etoposide—prostate cancer	3.88e-05	0.00034	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—prostate cancer	3.86e-05	0.000338	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Etoposide—prostate cancer	3.85e-05	0.000337	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.84e-05	0.000336	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—prostate cancer	3.82e-05	0.000335	CcSEcCtD
Haloperidol—Constipation—Etoposide—prostate cancer	3.81e-05	0.000334	CcSEcCtD
Haloperidol—Dizziness—Estradiol—prostate cancer	3.8e-05	0.000333	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—prostate cancer	3.8e-05	0.000333	CcSEcCtD
Haloperidol—Hypertension—Capecitabine—prostate cancer	3.8e-05	0.000333	CcSEcCtD
Haloperidol—Dry mouth—Docetaxel—prostate cancer	3.78e-05	0.000331	CcSEcCtD
Haloperidol—Confusional state—Docetaxel—prostate cancer	3.74e-05	0.000327	CcSEcCtD
Haloperidol—Anxiety—Capecitabine—prostate cancer	3.73e-05	0.000327	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.72e-05	0.000326	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—prostate cancer	3.71e-05	0.000325	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—prostate cancer	3.71e-05	0.000325	CcSEcCtD
Haloperidol—Oedema—Docetaxel—prostate cancer	3.71e-05	0.000325	CcSEcCtD
Haloperidol—Anaphylactic shock—Docetaxel—prostate cancer	3.71e-05	0.000325	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—prostate cancer	3.7e-05	0.000324	CcSEcCtD
Haloperidol—Vision blurred—Prednisone—prostate cancer	3.69e-05	0.000323	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—prostate cancer	3.68e-05	0.000322	CcSEcCtD
Haloperidol—Feeling abnormal—Etoposide—prostate cancer	3.67e-05	0.000322	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—prostate cancer	3.67e-05	0.000321	CcSEcCtD
Haloperidol—Diarrhoea—Mitoxantrone—prostate cancer	3.67e-05	0.000321	CcSEcCtD
Haloperidol—Dry mouth—Capecitabine—prostate cancer	3.66e-05	0.000321	CcSEcCtD
Haloperidol—Vomiting—Estradiol—prostate cancer	3.66e-05	0.00032	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—prostate cancer	3.66e-05	0.00032	CcSEcCtD
Haloperidol—Nervous system disorder—Docetaxel—prostate cancer	3.63e-05	0.000318	CcSEcCtD
Haloperidol—Thrombocytopenia—Docetaxel—prostate cancer	3.63e-05	0.000318	CcSEcCtD
Haloperidol—Rash—Estradiol—prostate cancer	3.63e-05	0.000318	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—prostate cancer	3.63e-05	0.000318	CcSEcCtD
Haloperidol—Dermatitis—Estradiol—prostate cancer	3.62e-05	0.000318	CcSEcCtD
Haloperidol—Anaemia—Prednisone—prostate cancer	3.62e-05	0.000317	CcSEcCtD
Haloperidol—Confusional state—Capecitabine—prostate cancer	3.62e-05	0.000317	CcSEcCtD
Haloperidol—Tachycardia—Docetaxel—prostate cancer	3.62e-05	0.000317	CcSEcCtD
Haloperidol—Headache—Estradiol—prostate cancer	3.6e-05	0.000316	CcSEcCtD
Haloperidol—Skin disorder—Docetaxel—prostate cancer	3.6e-05	0.000315	CcSEcCtD
Haloperidol—Agitation—Prednisone—prostate cancer	3.6e-05	0.000315	CcSEcCtD
Haloperidol—Oedema—Capecitabine—prostate cancer	3.59e-05	0.000314	CcSEcCtD
Haloperidol—Urticaria—Etoposide—prostate cancer	3.54e-05	0.00031	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—prostate cancer	3.53e-05	0.00031	CcSEcCtD
Haloperidol—Anorexia—Docetaxel—prostate cancer	3.53e-05	0.000309	CcSEcCtD
Haloperidol—Body temperature increased—Etoposide—prostate cancer	3.52e-05	0.000309	CcSEcCtD
Haloperidol—Nervous system disorder—Capecitabine—prostate cancer	3.52e-05	0.000308	CcSEcCtD
Haloperidol—Vertigo—Prednisone—prostate cancer	3.52e-05	0.000308	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—prostate cancer	3.52e-05	0.000308	CcSEcCtD
Haloperidol—Thrombocytopenia—Capecitabine—prostate cancer	3.51e-05	0.000308	CcSEcCtD
Haloperidol—Tachycardia—Capecitabine—prostate cancer	3.5e-05	0.000307	CcSEcCtD
Haloperidol—Skin disorder—Capecitabine—prostate cancer	3.49e-05	0.000305	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—prostate cancer	3.47e-05	0.000304	CcSEcCtD
Haloperidol—Hyperhidrosis—Capecitabine—prostate cancer	3.47e-05	0.000304	CcSEcCtD
Haloperidol—Hypotension—Docetaxel—prostate cancer	3.46e-05	0.000303	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—prostate cancer	3.46e-05	0.000303	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—prostate cancer	3.45e-05	0.000302	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—prostate cancer	3.43e-05	0.0003	CcSEcCtD
Haloperidol—Anorexia—Capecitabine—prostate cancer	3.42e-05	0.0003	CcSEcCtD
Haloperidol—Nausea—Estradiol—prostate cancer	3.42e-05	0.000299	CcSEcCtD
Haloperidol—Vomiting—Mitoxantrone—prostate cancer	3.41e-05	0.000299	CcSEcCtD
Haloperidol—Convulsion—Prednisone—prostate cancer	3.39e-05	0.000297	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—prostate cancer	3.39e-05	0.000297	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—prostate cancer	3.38e-05	0.000296	CcSEcCtD
Haloperidol—Hypertension—Prednisone—prostate cancer	3.38e-05	0.000296	CcSEcCtD
Haloperidol—Rash—Mitoxantrone—prostate cancer	3.38e-05	0.000296	CcSEcCtD
Haloperidol—Dermatitis—Mitoxantrone—prostate cancer	3.38e-05	0.000296	CcSEcCtD
Haloperidol—Headache—Mitoxantrone—prostate cancer	3.36e-05	0.000294	CcSEcCtD
Haloperidol—Hypotension—Capecitabine—prostate cancer	3.35e-05	0.000294	CcSEcCtD
Haloperidol—Insomnia—Docetaxel—prostate cancer	3.35e-05	0.000294	CcSEcCtD
Haloperidol—Anxiety—Prednisone—prostate cancer	3.32e-05	0.000291	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.31e-05	0.00029	CcSEcCtD
Haloperidol—Dyspnoea—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Haloperidol—Somnolence—Docetaxel—prostate cancer	3.29e-05	0.000289	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—prostate cancer	3.29e-05	0.000288	CcSEcCtD
Haloperidol—Hypersensitivity—Etoposide—prostate cancer	3.29e-05	0.000288	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—prostate cancer	3.27e-05	0.000286	CcSEcCtD
Haloperidol—Dyspepsia—Docetaxel—prostate cancer	3.26e-05	0.000286	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—prostate cancer	3.26e-05	0.000285	CcSEcCtD
Haloperidol—Insomnia—Capecitabine—prostate cancer	3.25e-05	0.000284	CcSEcCtD
Haloperidol—Decreased appetite—Docetaxel—prostate cancer	3.22e-05	0.000282	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—prostate cancer	3.21e-05	0.000282	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Docetaxel—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Haloperidol—Dyspnoea—Capecitabine—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Haloperidol—Oedema—Prednisone—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisone—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—prostate cancer	3.19e-05	0.00028	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—prostate cancer	3.19e-05	0.00028	CcSEcCtD
Haloperidol—Nausea—Mitoxantrone—prostate cancer	3.18e-05	0.000279	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—prostate cancer	3.18e-05	0.000278	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—prostate cancer	3.17e-05	0.000278	CcSEcCtD
Haloperidol—Constipation—Docetaxel—prostate cancer	3.17e-05	0.000278	CcSEcCtD
Haloperidol—Dyspepsia—Capecitabine—prostate cancer	3.16e-05	0.000277	CcSEcCtD
Haloperidol—Pruritus—Etoposide—prostate cancer	3.15e-05	0.000276	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—prostate cancer	3.14e-05	0.000275	CcSEcCtD
Haloperidol—Nervous system disorder—Prednisone—prostate cancer	3.13e-05	0.000275	CcSEcCtD
Haloperidol—Tachycardia—Prednisone—prostate cancer	3.12e-05	0.000273	CcSEcCtD
Haloperidol—Decreased appetite—Capecitabine—prostate cancer	3.12e-05	0.000273	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—prostate cancer	3.11e-05	0.000272	CcSEcCtD
Haloperidol—Skin disorder—Prednisone—prostate cancer	3.1e-05	0.000272	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Capecitabine—prostate cancer	3.1e-05	0.000271	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisone—prostate cancer	3.09e-05	0.000271	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—prostate cancer	3.08e-05	0.00027	CcSEcCtD
Haloperidol—Constipation—Capecitabine—prostate cancer	3.07e-05	0.000269	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—prostate cancer	3.06e-05	0.000268	CcSEcCtD
Haloperidol—Feeling abnormal—Docetaxel—prostate cancer	3.05e-05	0.000268	CcSEcCtD
Haloperidol—Diarrhoea—Etoposide—prostate cancer	3.05e-05	0.000267	CcSEcCtD
Haloperidol—Anorexia—Prednisone—prostate cancer	3.05e-05	0.000267	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—prostate cancer	3.04e-05	0.000267	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—prostate cancer	3.02e-05	0.000265	CcSEcCtD
Haloperidol—Feeling abnormal—Capecitabine—prostate cancer	2.96e-05	0.000259	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—prostate cancer	2.95e-05	0.000259	CcSEcCtD
Haloperidol—Dizziness—Etoposide—prostate cancer	2.95e-05	0.000258	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—prostate cancer	2.94e-05	0.000258	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—prostate cancer	2.94e-05	0.000258	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—prostate cancer	2.93e-05	0.000257	CcSEcCtD
Haloperidol—Body temperature increased—Docetaxel—prostate cancer	2.93e-05	0.000257	CcSEcCtD
Haloperidol—Insomnia—Prednisone—prostate cancer	2.89e-05	0.000253	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—prostate cancer	2.89e-05	0.000253	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—prostate cancer	2.88e-05	0.000252	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—prostate cancer	2.85e-05	0.00025	CcSEcCtD
Haloperidol—Urticaria—Capecitabine—prostate cancer	2.85e-05	0.00025	CcSEcCtD
Haloperidol—Body temperature increased—Capecitabine—prostate cancer	2.84e-05	0.000248	CcSEcCtD
Haloperidol—Vomiting—Etoposide—prostate cancer	2.84e-05	0.000248	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—prostate cancer	2.83e-05	0.000248	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—prostate cancer	2.83e-05	0.000248	CcSEcCtD
Haloperidol—Agitation—Epirubicin—prostate cancer	2.81e-05	0.000247	CcSEcCtD
Haloperidol—Dyspepsia—Prednisone—prostate cancer	2.81e-05	0.000246	CcSEcCtD
Haloperidol—Rash—Etoposide—prostate cancer	2.81e-05	0.000246	CcSEcCtD
Haloperidol—Dermatitis—Etoposide—prostate cancer	2.81e-05	0.000246	CcSEcCtD
Haloperidol—Headache—Etoposide—prostate cancer	2.79e-05	0.000245	CcSEcCtD
Haloperidol—Decreased appetite—Prednisone—prostate cancer	2.78e-05	0.000243	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—prostate cancer	2.75e-05	0.000241	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—prostate cancer	2.74e-05	0.00024	CcSEcCtD
Haloperidol—Constipation—Prednisone—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Haloperidol—Hypersensitivity—Docetaxel—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—prostate cancer	2.72e-05	0.000239	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—prostate cancer	2.67e-05	0.000234	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—prostate cancer	2.65e-05	0.000232	CcSEcCtD
Haloperidol—Nausea—Etoposide—prostate cancer	2.65e-05	0.000232	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—prostate cancer	2.64e-05	0.000232	CcSEcCtD
Haloperidol—Hypersensitivity—Capecitabine—prostate cancer	2.64e-05	0.000232	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisone—prostate cancer	2.63e-05	0.000231	CcSEcCtD
Haloperidol—Pruritus—Docetaxel—prostate cancer	2.62e-05	0.00023	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—prostate cancer	2.62e-05	0.000229	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—prostate cancer	2.6e-05	0.000228	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—prostate cancer	2.6e-05	0.000228	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.59e-05	0.000227	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—prostate cancer	2.55e-05	0.000223	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—prostate cancer	2.55e-05	0.000223	CcSEcCtD
Haloperidol—Urticaria—Prednisone—prostate cancer	2.54e-05	0.000222	CcSEcCtD
Haloperidol—Pruritus—Capecitabine—prostate cancer	2.54e-05	0.000222	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—prostate cancer	2.54e-05	0.000222	CcSEcCtD
Haloperidol—Diarrhoea—Docetaxel—prostate cancer	2.54e-05	0.000222	CcSEcCtD
Haloperidol—Body temperature increased—Prednisone—prostate cancer	2.53e-05	0.000221	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—prostate cancer	2.52e-05	0.000221	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Haloperidol—Oedema—Epirubicin—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—prostate cancer	2.46e-05	0.000215	CcSEcCtD
Haloperidol—Diarrhoea—Capecitabine—prostate cancer	2.45e-05	0.000215	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—prostate cancer	2.45e-05	0.000215	CcSEcCtD
Haloperidol—Dizziness—Docetaxel—prostate cancer	2.45e-05	0.000215	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—prostate cancer	2.45e-05	0.000214	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—prostate cancer	2.45e-05	0.000214	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—prostate cancer	2.44e-05	0.000214	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—prostate cancer	2.43e-05	0.000213	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—prostate cancer	2.4e-05	0.000211	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.4e-05	0.00021	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—prostate cancer	2.38e-05	0.000209	CcSEcCtD
Haloperidol—Dizziness—Capecitabine—prostate cancer	2.37e-05	0.000208	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—prostate cancer	2.36e-05	0.000207	CcSEcCtD
Haloperidol—Vomiting—Docetaxel—prostate cancer	2.36e-05	0.000206	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisone—prostate cancer	2.35e-05	0.000206	CcSEcCtD
Haloperidol—Rash—Docetaxel—prostate cancer	2.34e-05	0.000205	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—prostate cancer	2.34e-05	0.000205	CcSEcCtD
Haloperidol—Dermatitis—Docetaxel—prostate cancer	2.33e-05	0.000205	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—prostate cancer	2.33e-05	0.000204	CcSEcCtD
Haloperidol—Headache—Docetaxel—prostate cancer	2.32e-05	0.000203	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—prostate cancer	2.31e-05	0.000203	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—prostate cancer	2.31e-05	0.000203	CcSEcCtD
Haloperidol—Vomiting—Capecitabine—prostate cancer	2.28e-05	0.0002	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—prostate cancer	2.27e-05	0.000199	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Haloperidol—Rash—Capecitabine—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Haloperidol—Pruritus—Prednisone—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Haloperidol—Dermatitis—Capecitabine—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Haloperidol—Headache—Capecitabine—prostate cancer	2.25e-05	0.000197	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—prostate cancer	2.25e-05	0.000197	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—prostate cancer	2.24e-05	0.000196	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—prostate cancer	2.23e-05	0.000195	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—prostate cancer	2.22e-05	0.000195	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—prostate cancer	2.2e-05	0.000193	CcSEcCtD
Haloperidol—Nausea—Docetaxel—prostate cancer	2.2e-05	0.000193	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—prostate cancer	2.2e-05	0.000193	CcSEcCtD
Haloperidol—Diarrhoea—Prednisone—prostate cancer	2.19e-05	0.000192	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—prostate cancer	2.17e-05	0.00019	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—prostate cancer	2.16e-05	0.000189	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—prostate cancer	2.16e-05	0.000189	CcSEcCtD
Haloperidol—Constipation—Epirubicin—prostate cancer	2.14e-05	0.000187	CcSEcCtD
Haloperidol—Nausea—Capecitabine—prostate cancer	2.13e-05	0.000187	CcSEcCtD
Haloperidol—Dizziness—Prednisone—prostate cancer	2.11e-05	0.000185	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—prostate cancer	2.06e-05	0.000181	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—prostate cancer	2.04e-05	0.000178	CcSEcCtD
Haloperidol—Vomiting—Prednisone—prostate cancer	2.03e-05	0.000178	CcSEcCtD
Haloperidol—Rash—Prednisone—prostate cancer	2.02e-05	0.000177	CcSEcCtD
Haloperidol—Dermatitis—Prednisone—prostate cancer	2.01e-05	0.000176	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—prostate cancer	2.01e-05	0.000176	CcSEcCtD
Haloperidol—Headache—Prednisone—prostate cancer	2e-05	0.000175	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2e-05	0.000175	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—prostate cancer	1.99e-05	0.000174	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—prostate cancer	1.98e-05	0.000173	CcSEcCtD
Haloperidol—Loperamide—CYP3A4—prostate cancer	1.98e-05	0.142	CrCbGaD
Haloperidol—Body temperature increased—Epirubicin—prostate cancer	1.98e-05	0.000173	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—prostate cancer	1.91e-05	0.000167	CcSEcCtD
Haloperidol—Nausea—Prednisone—prostate cancer	1.9e-05	0.000166	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—prostate cancer	1.84e-05	0.000161	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—prostate cancer	1.84e-05	0.000161	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—prostate cancer	1.83e-05	0.00016	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—prostate cancer	1.77e-05	0.000155	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—prostate cancer	1.71e-05	0.00015	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—prostate cancer	1.7e-05	0.000149	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—prostate cancer	1.65e-05	0.000145	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—prostate cancer	1.64e-05	0.000143	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—prostate cancer	1.59e-05	0.000139	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—prostate cancer	1.58e-05	0.000139	CcSEcCtD
Haloperidol—Rash—Epirubicin—prostate cancer	1.58e-05	0.000138	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—prostate cancer	1.57e-05	0.000138	CcSEcCtD
Haloperidol—Headache—Epirubicin—prostate cancer	1.57e-05	0.000137	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—prostate cancer	1.53e-05	0.000134	CcSEcCtD
Haloperidol—Nausea—Epirubicin—prostate cancer	1.48e-05	0.00013	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—prostate cancer	1.47e-05	0.000129	CcSEcCtD
Haloperidol—Rash—Doxorubicin—prostate cancer	1.46e-05	0.000128	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—prostate cancer	1.46e-05	0.000128	CcSEcCtD
Haloperidol—Headache—Doxorubicin—prostate cancer	1.45e-05	0.000127	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—prostate cancer	1.37e-05	0.00012	CcSEcCtD
Haloperidol—DRD4—Signaling Pathways—MYC—prostate cancer	8.38e-07	8.95e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—prostate cancer	8.36e-07	8.93e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARA—prostate cancer	8.36e-07	8.93e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JAK2—prostate cancer	8.35e-07	8.92e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TYMS—prostate cancer	8.33e-07	8.9e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—prostate cancer	8.33e-07	8.9e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SRC—prostate cancer	8.3e-07	8.87e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NQO1—prostate cancer	8.29e-07	8.86e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—prostate cancer	8.24e-07	8.8e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.23e-07	8.79e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JAK2—prostate cancer	8.22e-07	8.78e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JAK2—prostate cancer	8.2e-07	8.76e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—prostate cancer	8.2e-07	8.76e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—prostate cancer	8.19e-07	8.75e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	8.18e-07	8.74e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TH—prostate cancer	8.17e-07	8.73e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MDM2—prostate cancer	8.15e-07	8.71e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—prostate cancer	8.12e-07	8.67e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—prostate cancer	8.09e-07	8.64e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—LPL—prostate cancer	8.08e-07	8.64e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	8.05e-07	8.6e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—prostate cancer	8.04e-07	8.58e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	8.03e-07	8.58e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—prostate cancer	8.03e-07	8.58e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MDM2—prostate cancer	8.02e-07	8.57e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—prostate cancer	8.01e-07	8.56e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MDM2—prostate cancer	8e-07	8.55e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—prostate cancer	8e-07	8.54e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—prostate cancer	7.98e-07	8.52e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—NOS3—prostate cancer	7.96e-07	8.51e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1B1—prostate cancer	7.95e-07	8.49e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CB—prostate cancer	7.93e-07	8.47e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CAV1—prostate cancer	7.93e-07	8.47e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—prostate cancer	7.91e-07	8.45e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—prostate cancer	7.89e-07	8.43e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—prostate cancer	7.87e-07	8.4e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CAV1—prostate cancer	7.86e-07	8.39e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—prostate cancer	7.85e-07	8.39e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—prostate cancer	7.82e-07	8.36e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1A1—prostate cancer	7.81e-07	8.34e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	7.8e-07	8.34e-06	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—prostate cancer	7.8e-07	8.33e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CB—prostate cancer	7.79e-07	8.32e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CB—prostate cancer	7.78e-07	8.31e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ERCC2—prostate cancer	7.74e-07	8.27e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—prostate cancer	7.74e-07	8.27e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—prostate cancer	7.71e-07	8.23e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GGT1—prostate cancer	7.7e-07	8.23e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—prostate cancer	7.66e-07	8.18e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—prostate cancer	7.62e-07	8.14e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NCOA1—prostate cancer	7.59e-07	8.1e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—prostate cancer	7.54e-07	8.06e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—prostate cancer	7.52e-07	8.04e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.51e-07	8.02e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—prostate cancer	7.5e-07	8.01e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—prostate cancer	7.48e-07	7.99e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP19A1—prostate cancer	7.48e-07	7.99e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—prostate cancer	7.44e-07	7.95e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—prostate cancer	7.44e-07	7.95e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—INS—prostate cancer	7.43e-07	7.94e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—prostate cancer	7.42e-07	7.93e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—prostate cancer	7.39e-07	7.89e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	7.38e-07	7.89e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—prostate cancer	7.38e-07	7.88e-06	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—prostate cancer	7.36e-07	7.86e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CB—prostate cancer	7.35e-07	7.85e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	7.32e-07	7.82e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—prostate cancer	7.31e-07	7.81e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—prostate cancer	7.29e-07	7.79e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—prostate cancer	7.28e-07	7.78e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—prostate cancer	7.28e-07	7.78e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—prostate cancer	7.28e-07	7.78e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—prostate cancer	7.28e-07	7.78e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CREBBP—prostate cancer	7.28e-07	7.77e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—INS—prostate cancer	7.25e-07	7.75e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—prostate cancer	7.25e-07	7.74e-06	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	7.24e-07	7.74e-06	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—prostate cancer	7.23e-07	7.72e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	7.23e-07	7.72e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—prostate cancer	7.22e-07	7.71e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RXRA—prostate cancer	7.21e-07	7.71e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—prostate cancer	7.18e-07	7.67e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—prostate cancer	7.17e-07	7.66e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—prostate cancer	7.16e-07	7.65e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—prostate cancer	7.16e-07	7.65e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—prostate cancer	7.15e-07	7.64e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARA—prostate cancer	7.14e-07	7.63e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—prostate cancer	7.14e-07	7.63e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—prostate cancer	7.13e-07	7.62e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—prostate cancer	7.11e-07	7.6e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—prostate cancer	7.11e-07	7.6e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CREBBP—prostate cancer	7.1e-07	7.59e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—prostate cancer	7.1e-07	7.58e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—prostate cancer	7.03e-07	7.51e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—prostate cancer	6.99e-07	7.47e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—prostate cancer	6.99e-07	7.46e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—prostate cancer	6.97e-07	7.45e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—prostate cancer	6.97e-07	7.44e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—COMT—prostate cancer	6.95e-07	7.42e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	6.92e-07	7.39e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—prostate cancer	6.92e-07	7.39e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—prostate cancer	6.9e-07	7.37e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CD—prostate cancer	6.9e-07	7.37e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—prostate cancer	6.89e-07	7.36e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—prostate cancer	6.88e-07	7.35e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—prostate cancer	6.88e-07	7.35e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1A—prostate cancer	6.87e-07	7.34e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—prostate cancer	6.85e-07	7.32e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—INS—prostate cancer	6.83e-07	7.3e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ITPR1—prostate cancer	6.81e-07	7.27e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	6.79e-07	7.25e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—prostate cancer	6.78e-07	7.24e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—INS—prostate cancer	6.77e-07	7.24e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—prostate cancer	6.77e-07	7.23e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	6.76e-07	7.22e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1A—prostate cancer	6.74e-07	7.2e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—prostate cancer	6.74e-07	7.2e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CD—prostate cancer	6.73e-07	7.19e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—prostate cancer	6.73e-07	7.19e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—prostate cancer	6.72e-07	7.18e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CAV1—prostate cancer	6.71e-07	7.17e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CREBBP—prostate cancer	6.69e-07	7.15e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—prostate cancer	6.68e-07	7.14e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CREBBP—prostate cancer	6.64e-07	7.09e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—prostate cancer	6.58e-07	7.03e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—prostate cancer	6.57e-07	7.02e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—prostate cancer	6.56e-07	7.01e-06	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—prostate cancer	6.56e-07	7.01e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—prostate cancer	6.54e-07	6.98e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—prostate cancer	6.53e-07	6.98e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NOS3—prostate cancer	6.52e-07	6.96e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TYMS—prostate cancer	6.43e-07	6.87e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—prostate cancer	6.43e-07	6.87e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—prostate cancer	6.42e-07	6.85e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.41e-07	6.85e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—prostate cancer	6.41e-07	6.85e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—prostate cancer	6.4e-07	6.84e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—prostate cancer	6.4e-07	6.84e-06	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—prostate cancer	6.37e-07	6.81e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NOS3—prostate cancer	6.36e-07	6.79e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—prostate cancer	6.36e-07	6.79e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SRC—prostate cancer	6.35e-07	6.79e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—prostate cancer	6.35e-07	6.78e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CD—prostate cancer	6.35e-07	6.78e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—prostate cancer	6.32e-07	6.75e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—prostate cancer	6.3e-07	6.73e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CD—prostate cancer	6.29e-07	6.72e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SRC—prostate cancer	6.25e-07	6.68e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—LPL—prostate cancer	6.24e-07	6.67e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SRC—prostate cancer	6.24e-07	6.67e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—prostate cancer	6.19e-07	6.62e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—prostate cancer	6.19e-07	6.61e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—prostate cancer	6.13e-07	6.55e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—prostate cancer	6.12e-07	6.53e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—prostate cancer	6.11e-07	6.53e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—prostate cancer	6.09e-07	6.51e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—prostate cancer	6.08e-07	6.49e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—prostate cancer	6.06e-07	6.47e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—prostate cancer	6.03e-07	6.44e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—prostate cancer	6.03e-07	6.44e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A1—prostate cancer	6.03e-07	6.44e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—prostate cancer	6.02e-07	6.43e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CB—prostate cancer	6.01e-07	6.43e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—prostate cancer	6.01e-07	6.42e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NOS3—prostate cancer	5.99e-07	6.4e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ERCC2—prostate cancer	5.98e-07	6.38e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—prostate cancer	5.96e-07	6.37e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NOS3—prostate cancer	5.94e-07	6.35e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—prostate cancer	5.9e-07	6.31e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CB—prostate cancer	5.87e-07	6.27e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—prostate cancer	5.82e-07	6.21e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—prostate cancer	5.81e-07	6.21e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—INS—prostate cancer	5.79e-07	6.18e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—prostate cancer	5.69e-07	6.08e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—prostate cancer	5.68e-07	6.07e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CREBBP—prostate cancer	5.67e-07	6.06e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—prostate cancer	5.67e-07	6.06e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—prostate cancer	5.62e-07	6e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—prostate cancer	5.6e-07	5.99e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—prostate cancer	5.59e-07	5.98e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—prostate cancer	5.59e-07	5.97e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—prostate cancer	5.59e-07	5.97e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—prostate cancer	5.58e-07	5.96e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—prostate cancer	5.57e-07	5.95e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—prostate cancer	5.55e-07	5.93e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CB—prostate cancer	5.53e-07	5.91e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARA—prostate cancer	5.51e-07	5.89e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CB—prostate cancer	5.48e-07	5.86e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—prostate cancer	5.48e-07	5.86e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—prostate cancer	5.48e-07	5.85e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—prostate cancer	5.47e-07	5.84e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—prostate cancer	5.43e-07	5.8e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CD—prostate cancer	5.38e-07	5.74e-06	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—prostate cancer	5.36e-07	5.73e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—prostate cancer	5.26e-07	5.62e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—prostate cancer	5.23e-07	5.59e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—prostate cancer	5.2e-07	5.55e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CAV1—prostate cancer	5.18e-07	5.54e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—prostate cancer	5.18e-07	5.53e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—prostate cancer	5.17e-07	5.52e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—prostate cancer	5.16e-07	5.51e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NOS3—prostate cancer	5.08e-07	5.42e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—prostate cancer	5.07e-07	5.42e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—prostate cancer	4.96e-07	5.29e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—prostate cancer	4.84e-07	5.17e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—prostate cancer	4.83e-07	5.16e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—prostate cancer	4.78e-07	5.11e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	4.76e-07	5.08e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—prostate cancer	4.75e-07	5.07e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—prostate cancer	4.74e-07	5.07e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—prostate cancer	4.74e-07	5.06e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—prostate cancer	4.72e-07	5.04e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CB—prostate cancer	4.69e-07	5.01e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—prostate cancer	4.68e-07	5e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—prostate cancer	4.64e-07	4.96e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—prostate cancer	4.6e-07	4.92e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—prostate cancer	4.59e-07	4.91e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—prostate cancer	4.56e-07	4.87e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—prostate cancer	4.52e-07	4.83e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—prostate cancer	4.48e-07	4.79e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—INS—prostate cancer	4.47e-07	4.77e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CREBBP—prostate cancer	4.38e-07	4.68e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—prostate cancer	4.28e-07	4.57e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—prostate cancer	4.21e-07	4.5e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—prostate cancer	4.2e-07	4.49e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CD—prostate cancer	4.15e-07	4.43e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—prostate cancer	4.05e-07	4.33e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—prostate cancer	3.95e-07	4.22e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NOS3—prostate cancer	3.92e-07	4.19e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—prostate cancer	3.89e-07	4.15e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—prostate cancer	3.88e-07	4.14e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—prostate cancer	3.87e-07	4.14e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—prostate cancer	3.86e-07	4.13e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—prostate cancer	3.67e-07	3.92e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—prostate cancer	3.66e-07	3.91e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CB—prostate cancer	3.62e-07	3.86e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—prostate cancer	3.58e-07	3.83e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—prostate cancer	3.58e-07	3.82e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—prostate cancer	3.37e-07	3.6e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—prostate cancer	3.34e-07	3.57e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—prostate cancer	3.13e-07	3.34e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—prostate cancer	3e-07	3.2e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—prostate cancer	2.98e-07	3.18e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—prostate cancer	2.92e-07	3.12e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—prostate cancer	2.86e-07	3.05e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—prostate cancer	2.75e-07	2.94e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—prostate cancer	2.73e-07	2.92e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—prostate cancer	2.33e-07	2.49e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.2e-07	2.36e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—prostate cancer	1.8e-07	1.92e-06	CbGpPWpGaD
